These seemingly contradictory effects of CAP on histone acetylation in these two studies can be explained by the significant differences of cell signaling networks at the healthy and malignant states that may potentially justify the use of HDAC inhibitors with CAP for selective targeting of cancer cells. The gene discussed is BRD4; the disease is cancer.